Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5894.084 | 0.9923 | 0.9903 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5894.084 | 1.0313 | 1.0391 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5894.084 | 0.8522 | 0.8087 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5894.084 | 0.4091 | 0.1401 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5894.084 | 0.1545 | -0.3821 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5894.084 | 0.1944 | -0.2859 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5894.084 | 0.0775 | -0.5995 | 1.5903 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 5895.085 | 1.0110 | 1.0153 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 5895.085 | 1.0342 | 1.0472 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 5895.085 | 1.0346 | 1.0478 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 5895.085 | 0.9993 | 0.9991 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 5895.085 | 1.0246 | 1.0341 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 5895.085 | 0.3707 | 0.0039 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 5895.085 | 0.2910 | -0.1515 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 5895.085 | 0.1144 | -0.5564 | 1.4396 | |
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 5895.085 | 0.0863 | -0.6352 | 1.4396 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5896.084 | 0.9647 | 0.9533 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5896.084 | 1.0011 | 1.0015 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5896.084 | 1.1166 | 1.1506 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5896.084 | 1.1544 | 1.1982 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5896.084 | 1.0315 | 1.0412 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5896.084 | 0.4335 | 0.1540 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5896.084 | 0.2100 | -0.2837 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5896.084 | 0.1807 | -0.3511 | 1.5200 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5896.084 | 0.0210 | -0.8428 | 1.5200 |